What question did this study set out to answer?

This review aims to summarize drug-drug interactions (DDIs) involving direct oral anticoagulants (DOACs) and their clinical significance.

May 24, 2022PharmaceuticsOpen Access

Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice

View Full Paper

Ask AI

Bookmark

Why the study?

Comorbidity and polypharmacy can cause relevant drug-drug interactions by affecting the exposure or pharmacological activities of DOACs, compromising their safety profile in multimorbid patients.

What are the potential drug-drug interactions of DOACs and how should they be managed in clinical practice?

Design

Review

Authors

NFNicola FerriUniversity of Padua ECE. ColomboUniversity of Milan MTMarco TenconiItalfarmaco (Italy)

Discussion

Member takes

Implication

Supports preferring DOACs to reduce DDI burden; leaves open precise interaction risks and management protocols.

Key Points

This review aims to summarize drug-drug interactions (DDIs) involving direct oral anticoagulants (DOACs) and their clinical significance.
Systematic analysis of potential DDIs between DOACs and other drug classes
Evaluation of pharmacokinetic properties of DOACs
Discussion of management strategies to mitigate DDIs.
DOACs show fewer clinically relevant DDIs compared to warfarin
Significant DDIs are noted particularly in elderly patients with multimorbidity
Management strategies include dosage reduction and timing adjustments to minimize DDI incidence.

Structured PICO

What are the potential drug-drug interactions of DOACs and how should they be managed in clinical practice?

Population

Patients requiring anticoagulation for non-valvular atrial fibrillation (NVAF), venous thromboembolism (VTE), or recent acute coronary syndrome (ACS), particularly elderly patients with multimorbidity and polypharmacy.

Intervention

Direct oral anticoagulants (DOACs: dabigatran, rivaroxaban, apixaban, edoxaban) co-administered with other drugs.

Outcome

Potential drug-drug interactions (DDIs) affecting exposure or pharmacological activities of DOACs.safety

While DOACs have fewer drug-drug interactions than warfarin, their co-administration with P-glycoprotein or CYP modulators requires careful evaluation to avoid adverse bleeding or thrombotic events.

Cite This Study

Ferri et al. (2022) studied this question.

synapsesocial.com/papers/69dd5dcd7dbdc4ad1440c6a0 https://doi.org/10.3390/pharmaceutics14061120

View Full Paper

Ask AI

Bookmark

Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider